ผลของนวัตกรรมคู่หูดูแลกันต่อการประเมินภาวะแทรกซ้อนที่เท้าจากเบาหวานในผู้ที่เป็นโรคเบาหวานชนิดที่ 2 ในตำบลห้วยไคร้ อำเภอแม่สายจังหวัดเชียงราย

Abstract

Diabetic foot complications affect quality of life for diabetes patients considerably, resulting in disability and sometimes death. The Buddy Care innovation is a healthcare innovation which encourages diabetic foot screening with buddy assistance to monitor and notify for self-care to prevent diabetic foot complications. This quasi-experimental study aimed to compare the number of participants who correctly screened their diabetic foot complications in patients with type 2 diabetes in innovative buddy care groups. The findings were evaluated both before and after innovation utilization, including comparison between participants in buddy care groups and those who received standard treatment. The participants were chosen by purposive sampling based on inclusion criteria and consisted of 40 patients with type 2 diabetes divided into an experimental group of 20 people and a control group of 20. The research tools were: The instruments for operation, which included: 1) activity planning for the buddy care innovation to screen for diabetic feet complications in patients with type 2 diabetes based on Bandura’s self-regulation theory (Bandura, 1986) . It consisted of 3 phases: selfobservation, judgment process, and self-reaction associated with self-regulation encouragement by offering individuals who could encourage, monitor and provide positive reinforcement, also called Buddy Care; 2) the diabetic foot complications screening handbook, and 3) a training plan for diabetic foot complications assessment skills. The tools for data gathering were a general information questionnaire and an observation form for diabetic foot complication screening, with a content validity value of 1.0 and reliability value of 1.0. The data was analyzed using McNemar’s Test and Chi-square Test. The results revealed that after using the buddy care innovation, the number of participants who correctly assessed diabetic foot complications in patients with type 2 diabetes in the experimental group was higher than before using the buddy care innovation (statistically significant at p < 0.001), and higher than the group of participants who received standard treatment (statistically significant at p < 0.01). The findings indicate that the buddy care innovation could be used to enhance diabetic foot complication screening, as well as effectively preventing diabetic foot complication.